Page 2333 - Hematology_ Basic Principles and Practice ( PDFDrive )
P. 2333

Chapter 139  Disseminated Intravascular Coagulation  2075


            21.  Isbister GK: Snake bite doesn’t cause disseminated intravascular coagula-  28.  Bernard  GR,  Vincent  JL,  Laterre  PF,  et al:  Efficacy  and  safety  of
               tion: Coagulopathy and thrombotic microangiopathy in snake envenom-  recombinant human activated protein C for severe sepsis. N Engl J Med
               ing. Semin Thromb Hemost 36:444–451, 2010.            344:699–709, 2001.
            22.  Levi M, de Jonge E, Meijers J: The diagnosis of disseminated intravas-  29.  Levi M, de Jonge E, van der Poll T: Rationale for restoration of physi-
               cular coagulation. Blood Rev 16(4):217–223, 2002.     ological anticoagulant pathways in patients with sepsis and disseminated
            23.  Levi M, Meijers JC: DIC: Which laboratory tests are most useful. Blood   intravascular coagulation. Crit Care Med 29:S90–S94, 2001.
               Rev 2010.                                          30.  de  Jonge  E,  van  der  Poll T,  Kesecioglu  J,  et al:  Anticoagulant  factor
            24.  Dempfle CE, Borggrefe M: Point of care coagulation tests in critically ill   concentrates in disseminated intravascular coagulation: rationale for use
               patients. Semin Thromb Hemost 34(5):445–450, 2008.    and clinical experience. Semin Thromb Hemost 27:667–674, 2001.
            25.  Levi M, Levy M, Williams MD, et al: Prophylactic heparin in patients   31.  Warren BL, Eid A, Singer P, et al: Caring for the critically ill patient.
               with severe sepsis treated with drotrecogin alfa (activated). Am J Respir   High-dose  antithrombin  III  in  severe  sepsis:  a  randomized  controlled
               Crit Care Med 176(5):483–490, 2007.                   trial. JAMA 286(15):1869–1878, 2001.
            26.  Abraham E, Reinhart K, Opal S, et al: Efficacy and safety of tifacogin   32.  Levi  M:  Activated  protein  C  in  sepsis:  a  critical  review.  Curr  Opin
               (recombinant tissue factor pathway inhibitor) in severe sepsis: a random-  Hematol 15(5):481–486, 2008.
               ized controlled trial. JAMA 290(2):238–247, 2003.
            27.  Yamakawa K, Aihara M, Ogura H, et al: Recombinant human soluble
               thrombomodulin in severe sepsis: a systematic review and meta-analysis.
               J Thromband Haemost 13(4):508–519, 2015.
   2328   2329   2330   2331   2332   2333   2334   2335   2336   2337   2338